Figure 4.

miR-375 is a candidate master regulator of cancer pathways in FLC. (A) Expression of miR-375 in CHOL (n = 36), LIHC (n = 366), and FLC (n = 6) in TCGA smRNA-seq data. (B) Log₂ (fold change) of miR-375 expression in different tumor types (n = 23) within TCGA. The size of each circle represents the geometric mean of miR-375 expression in each tumor type. Each tumor type is ranked on the y-axis by the log₂ (fold change) of the geometric mean of tumor expression over non–tumor expression of miR-375. Geometric means were used instead of arithmetic means to provide robustness to outliers. Highlighted are FLC (red) as well as CHOL and LIHC (blue). (C) Ranked –log₂ (P value) of miRhub Monte Carlo simulation. miRNAs were examined for target site enrichment in genes up-regulated in FLC. Dotted line represents P = .05. (D) KEGG enrichment analysis of up-regulated miR-375 target genes in FLC. **P < .01, ***P < .001 (Mann–Whitney U test, 2-sided). BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal papillary cell carcinoma; KIRP, kidney renal clear cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma.